<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Opioid Use Disorder &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/opioid-use-disorder/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Jan 2026 07:49:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Opioid Use Disorder &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Exploring Incentives for Buprenorphine Treatment in Family Medicine</title>
		<link>https://bioengineer.org/exploring-incentives-for-buprenorphine-treatment-in-family-medicine/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 07:48:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Family Medicine** **Açıklama:** 1. **Buprenorphine Treatment:** Makalenin temel odağı olan tedavi yöntemi. 2. **Incentive Programs]]></category>
		<category><![CDATA[Incentive Programs]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **Buprenorphine Treatment]]></category>
		<category><![CDATA[Makale içeriği ve başlık dikkate alındığında en uygun 5 etiket şunlardır: **Buprenorphine Treatment]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Patient Adherence]]></category>
		<guid isPermaLink="false">https://bioengineer.org/exploring-incentives-for-buprenorphine-treatment-in-family-medicine/</guid>

					<description><![CDATA[In recent years, the opioid crisis has escalated into a public health emergency, with millions of individuals affected by opioid use disorder (OUD). Traditional treatment options have often fallen short, leaving healthcare providers and patients alike struggling to find effective strategies. A promising avenue of exploration has emerged from a recent study that delves into [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320953</post-id>	</item>
		<item>
		<title>Medication for Opioid Disorder Enhances Patient Discharge Rates</title>
		<link>https://bioengineer.org/medication-for-opioid-disorder-enhances-patient-discharge-rates/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 05:45:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[healthcare policy]]></category>
		<category><![CDATA[içerik ve terminoloji İngilizce olduğundan etiketler İngilizce olarak üretilmiştir): **Medication-Assisted Treatment]]></category>
		<category><![CDATA[İşte 5 uygun etiket (Türkçe başlığa rağmen]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış olarak): **Opioid Use Disorder Treatment]]></category>
		<category><![CDATA[Medication-Assisted Treatment (MOUD)]]></category>
		<category><![CDATA[Opioid Crisis Public Health**]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Patient Discharge Rates]]></category>
		<category><![CDATA[Patient Retention]]></category>
		<category><![CDATA[Treatment Outcomes** **Açıklama:** 1. **Medication-Assisted Treatment (MAT):]]></category>
		<guid isPermaLink="false">https://bioengineer.org/medication-for-opioid-disorder-enhances-patient-discharge-rates/</guid>

					<description><![CDATA[In recent years, the escalating opioid crisis has emerged as one of the most pressing public health challenges. An increasing number of individuals are searching for effective treatments for Opioid Use Disorder (OUD), a condition that has severe implications not only for the individuals affected but also for families and entire communities. As health practitioners [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320933</post-id>	</item>
		<item>
		<title>Rapid Low-Dose Buprenorphine Induction in Fentanyl Users</title>
		<link>https://bioengineer.org/rapid-low-dose-buprenorphine-induction-in-fentanyl-users/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 18:35:45 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[addiction medicine]]></category>
		<category><![CDATA[buprenorphine induction]]></category>
		<category><![CDATA[fentanyl addiction treatment]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[rapid induction protocol]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rapid-low-dose-buprenorphine-induction-in-fentanyl-users/</guid>

					<description><![CDATA[A groundbreaking advancement in the field of addiction treatment has emerged with the introduction of a simplified, rapid low-dose buprenorphine induction method specifically designed for individuals using fentanyl. This innovative approach is documented in a compelling case series by researchers R. Alexander and N. Woford, published in the esteemed journal Addictive Sciences Clinical Practice. With [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319957</post-id>	</item>
		<item>
		<title>Innovative Remote Program for Opioid Use Disorder Pilot Test</title>
		<link>https://bioengineer.org/innovative-remote-program-for-opioid-use-disorder-pilot-test/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 13:07:41 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Hospitalized Patients Care** **Açıklama:** 1. **Opioid Use Disorder Treatment:** Makalenin temel konusu ve tedavi edilen durum. 2. **Remote Outpatient Program:** Araştırmanın test ettiği yenilik]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış): **Opioid Use Disorder Treatment]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Outpatient Program]]></category>
		<category><![CDATA[Pilot Study]]></category>
		<category><![CDATA[Remote Outpatient Program]]></category>
		<category><![CDATA[Remote Treatment]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[Telehealth in Addiction]]></category>
		<guid isPermaLink="false">https://bioengineer.org/innovative-remote-program-for-opioid-use-disorder-pilot-test/</guid>

					<description><![CDATA[A novel approach to combat one of the most pressing public health crises of our time has recently emerged, revealing the potential effectiveness of remotely delivered intensive outpatient programs for patients grappling with opioid use disorder (OUD). This innovative pilot study, conducted by Szpak, Velez, Prostko, and colleagues, uncovers significant insights that can shape future [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317934</post-id>	</item>
		<item>
		<title>Enhancing Buprenorphine Access Through Library Telehealth</title>
		<link>https://bioengineer.org/enhancing-buprenorphine-access-through-library-telehealth/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 03:01:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[and existing keywords/tags]]></category>
		<category><![CDATA[Based on the content]]></category>
		<category><![CDATA[Buprenorphine Access]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Health equity** **Açıklama:** 1. **Library telehealth:** Çalışmanın temel yenilikçi yöntemini (kütüphaneler aracılığıyla tele-sağlık) doğrudan vurgular. 2. **]]></category>
		<category><![CDATA[here are 5 appropriate tags focusing on core concepts and avoiding redundancy with the provided keywords: **Library Telehealth]]></category>
		<category><![CDATA[Homelessness Healthcare]]></category>
		<category><![CDATA[Homelessness interventions]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **Library telehealth]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Telehealth Intervention]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-buprenorphine-access-through-library-telehealth/</guid>

					<description><![CDATA[In an increasingly technology-driven world, the intersection of healthcare accessibility and telehealth has become a focal point for innovations aimed at addressing critical public health challenges. One such challenge is the treatment of opioid use disorder among vulnerable populations, particularly individuals experiencing homelessness. A groundbreaking study, titled “Bupe by the book,” promises to investigate the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317876</post-id>	</item>
		<item>
		<title>Evidence Lacking: Genetic Testing’s Role in Assessing Opioid Misuse Risk</title>
		<link>https://bioengineer.org/evidence-lacking-genetic-testings-role-in-assessing-opioid-misuse-risk/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 09 Jan 2025 17:16:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Genetic Testing]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Psychiatric Genetics]]></category>
		<category><![CDATA[public health crisis]]></category>
		<category><![CDATA[Risk Assessment Accuracy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evidence-lacking-genetic-testings-role-in-assessing-opioid-misuse-risk/</guid>

					<description><![CDATA[Opioid misuse remains one of the most pressing public health challenges in the United States, representing a multi-faceted crisis that affects millions. Recent statistics reveal that over 6 million Americans aged 12 and older met the clinical criteria for Opioid Use Disorder (OUD) in 2022. This staggering figure emphasizes the urgent need for effective interventions [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233456</post-id>	</item>
		<item>
		<title>Racial, economic barriers hinder access to medicine for treating opioid use disorder</title>
		<link>https://bioengineer.org/racial-economic-barriers-hinder-access-to-medicine-for-treating-opioid-use-disorder/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Thu, 15 Aug 2024 00:08:53 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Buprenorphine Dispensing]]></category>
		<category><![CDATA[Economic Barriers]]></category>
		<category><![CDATA[Healthcare Access Inequities]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Racial Segregation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/racial-economic-barriers-hinder-access-to-medicine-for-treating-opioid-use-disorder/</guid>

					<description><![CDATA[PORTLAND, Ore. – Patients with a prescription for an opioid use disorder medication may have a tough time getting it filled if their pharmacy is in a community that’s racially and economically segregated, according to a new study led by scientists at Oregon State University and Johns Hopkins University. PORTLAND, Ore. – Patients with a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">231564</post-id>	</item>
		<item>
		<title>Secret shopper study sheds light on barriers to opioid treatment for women</title>
		<link>https://bioengineer.org/secret-shopper-study-sheds-light-on-barriers-to-opioid-treatment-for-women/</link>
					<comments>https://bioengineer.org/secret-shopper-study-sheds-light-on-barriers-to-opioid-treatment-for-women/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 03 Jun 2021 20:42:41 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Addiction]]></category>
		<category><![CDATA[Behavior]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Healthcare Stigma]]></category>
		<category><![CDATA[Medicaid Disparities]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Mental Health]]></category>
		<category><![CDATA[Opioid Use Disorder]]></category>
		<category><![CDATA[Parenting/Child Care/Family]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Pregnant Women Health]]></category>
		<category><![CDATA[Public Health]]></category>
		<category><![CDATA[Treatment Access Barriers]]></category>
		<guid isPermaLink="false">https://bioengineer.org/secret-shopper-study-sheds-light-on-barriers-to-opioid-treatment-for-women/</guid>

					<description><![CDATA[After a 2020 Vanderbilt University Medical Center study showed women have a difficult time accessing treatment for opioid use disorder (OUD), investigators analyzed comments received from the study&#8217;s participants to further shed light on barriers to care, which included everything from long on-hold times to difficult interactions with clinic receptionists during phone calls seeking appointments. [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/secret-shopper-study-sheds-light-on-barriers-to-opioid-treatment-for-women/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">170931</post-id>	</item>
	</channel>
</rss>
